United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company's stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $518.39, for a total transaction of $4,924,705.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $168,188,006.77. This represents a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
United Therapeutics Stock Down 0.0%
Shares of NASDAQ:UTHR opened at $512.88 on Tuesday. The firm has a fifty day moving average of $532.35 and a two-hundred day moving average of $538.04. United Therapeutics Corporation has a 12-month low of $302.19 and a 12-month high of $609.35. The firm has a market capitalization of $22.00 billion, a P/E ratio of 18.35, a price-to-earnings-growth ratio of 1.74 and a beta of 0.59.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same period in the prior year, the business posted $6.41 earnings per share. United Therapeutics's revenue for the quarter was down 1.9% compared to the same quarter last year. Equities research analysts expect that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Torren Management LLC bought a new position in shares of United Therapeutics in the 4th quarter valued at approximately $26,000. Toth Financial Advisory Corp boosted its position in United Therapeutics by 2,400.0% during the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company's stock worth $27,000 after purchasing an additional 48 shares during the period. Activest Wealth Management boosted its position in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 56 shares during the period. Fiduciary Financial Advisors acquired a new position in United Therapeutics during the second quarter valued at approximately $30,000. Finally, WealthCollab LLC grew its holdings in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on UTHR shares. JPMorgan Chase & Co. raised their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a research note on Thursday, July 23rd. Royal Bank Of Canada dropped their price objective on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Wells Fargo & Company raised shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research note on Thursday, August 6th. Finally, TD Cowen reissued a "buy" rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $646.00.
Read Our Latest Analysis on UTHR
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
